CELC vs ALTI Comparison

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments that includes Wealth Management and Strategic Alternatives. Wealth Management includes providing holistic solutions for their wealth management clients through their comprehensive range of wealth management services, including investment management and advisory services. Strategic Alternatives segment, it assists their investors with alternative investments and co-investments by providing access to highly differentiated opportunities in these areas.